Dual Rod Posterior Instrumentation Without Fusion for the Treatment of Progressive Early Onset Scoliosis: A Multicenter Study**

Behrooz A. Akbarnia, MD
Medical Director
San Diego Center for Spinal Disorders
La Jolla, CA
David S. Marks, FRCS
Royal Orthopaedic Hospital
Birmingham, United Kingdom
Oheneba Boachie-Adjei, M.D.
Hospital for Special Surgery
New York, NY
et al
Exhibit from the SRS 2002 Annual Meeting
· (a – DePuy AcroMed; b – DePuy AcroMed)

PURPOSE: This multicenter study was initiated to evaluate the efficacy and safety of a dual rod technique in achieving additional stability and maintaining correction while allowing spinal growth.

METHODS: Thirty-eight patients had dual rod constructs utilizing a connector for periodic lengthening. All procedures were primary. There were 14 patients with infantile and juvenile idiopathic scoliosis, 6 congenital, 3 neuromuscular and 15 had other etiologies. All patients had previous unsuccessful bracing or casting. The mean age at surgery was 70 months. Followup averaged 44 months.

RESULTS: The mean pre-operative Cobb angle and kyphosis were 76 degrees and 50 degrees respectively. The Cobb angle measurement improved from 76 degrees to 38 degrees. Kyphosis changed from 50 degrees to 38 degrees. T1-S1 length increased an average 4.7 cm after first surgery (elongation) and growth was 3.55 cm during the follow-up period. In addition to initial elongation, the growth rate was an average of 1 cm/year. Implant complications included 1 hook dislodgements and 1 broken rods. No significant crank shaft phenomenon was noted. CONCLUSION: The dual rod technique is safe and effective, provides better stability, reduces complications and allows continued spinal growth in this challenging patient population.

· If noted, the author indicates something of value received. The codes are identified as: a-research or institutional support; b-miscellaneous funding; c-royalties; d-stock options.

** The FDA has not cleared a drug and/or medical device for the use described in this presentation (i.e., the drug or medical device is being discussed in an “off-label” use).
Last Updated: 04/26/2005